Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer

Insurance coverage policies are a major determinant of patient access to genomic tests. The objective of this study was to examine differences in coverage policies for guideline-recommended pharmacogenomic tests that inform cancer treatment. We analyzed coverage policies from eight Medicare contract...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Christine Y., Loomer, Stephanie, Ceccarelli, Rachel, Mazor, Kathleen M., Sabin, James, Clayton, Ellen Wright, Ginsburg, Geoffrey S., Wu, Ann Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023380/
https://www.ncbi.nlm.nih.gov/pubmed/29772692
http://dx.doi.org/10.3390/jpm8020019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023380/
https://www.ncbi.nlm.nih.gov/pubmed/29772692
http://dx.doi.org/10.3390/jpm8020019

Ejemplares similares